Day: January 26, 2026

ProPhase Labs Provides Crown Medical Collections Update; 250+ Insurance Payors Engaged, Approximately 50 Matters in Advanced Settlement Posture

UNIONDALE, NY, Jan. 26, 2026 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (OTC: PRPH) (“ProPhase” or the “Company”), a next-generation biotech,...

Minerva Neurosciences to Host Virtual KOL Event to Discuss Roluperidone: From Unmet Need to Reality – Potentially the First Treatment for Patients with Negative Symptoms of Schizophrenia, on February 3, 2026

BURLINGTON, Mass., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the...

MannKind Announces FDA Approval of Updated Afrezza® Label Providing Starting Dose Guidance when Switching from Multiple Daily Injections (MDI) or Insulin Pump Mealtime Therapy

Updated initial conversion table based on clinical trials in adults showing significantly improved mealtime glycemic excursions DANBURY, Conn. and WESTLAKE...

Cheelcare Announces Medicare and Medicaid Services Reimbursement Approval for Companion Power Assist Device, Expanding U.S. Market Access

Investment Highlights:U.S. Medicare and Medicaid reimbursement eligibility achieved:The Company has received Pricing, Data Analysis, and Coding ("PDAC") verification, enabling U.S....

BioNxt Accelerates ODF for Multiple Sclerosis Toward Human Clinical Study with >40% Bioavailability Improvement and Myasthenia Gravis Expansion

VANCOUVER, BC / ACCESS Newswire / January 26, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience...

error: Content is protected !!